Leading Russian orthopedists and rheumatologists discuss comprehensive approach to treating osteoarthritis

A third of the global population aged 25 to 75 has signs of osteoarthritis^[1], a chronic disease causing joint damage. The standard comprehensive approach to treating such patients includes non-pharmaceutical, pharmacological and surgical methods. However, a large proportion of patients are not satisfied with the treatment, as doctors said at the 7th International Congress of the Association of Rheumatic Disease Surgeons, held in Moscow.

Experts reviewed the results of a multicenter, prospective, double-blind, placebo-controlled, randomized study with 212 patients aged 40 to 75 years with stage 2 and 3 osteoarthritis and severe pain syndrome. The study examined Artneo^®, a complex remedy for joint health containing native type II collagen and boswellic acids.

The specialized WOMAC scale was used in the study. The WOMAC scale contains 24 questions, divided into three domains: pain (5 questions), stiffness (2 questions) and joint function (17 questions).

According to the data presented by Lyudmila Alekseeva, the Artneo^® group showed a halved WOMAC pain score in 48.1% of patients, and a more than twofold reduction in stiffness according to the WOMAC was noted in 41.3% of people. A decrease by a factor of two or more in the total WOMAC score was observed in 76.9% of patients.

The professor added that today doctors are increasingly taking a comprehensive approach to treating patients:

The multiagent complex Artneo^® has a beneficial effect on the functional state of joints, helping to protect their tissues from destruction and promoting their natural renewal. It also helps reduce discomfort, swelling, pain and stiffness.